Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aim...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Oncol
Asıl Yazarlar: Urup, Thomas, Gillberg, Linn, Kaastrup, Katja, Lü, Maya Jeje Schuang, Michaelsen, Signe Regner, Andrée Larsen, Vibeke, Christensen, Ib Jarle, Broholm, Helle, Lassen, Ulrik, Grønbæk, Kirsten, Poulsen, Hans Skovgaard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7191184/
https://ncbi.nlm.nih.gov/pubmed/32133779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12660
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller